If you have been reading about thymalfasin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
==== Trigger (induction) ==== Platelet activation begins seconds after adhesion occurs. It is triggered when collagen from the subendothelium binds with its receptors (GPVI receptor and integrin α2β1) on the platelet. GPVI is associated with the Fc receptor gamma chain and leads via the activation of a tyrosine kinase cascade finally to the activation of PLC-gamma2 (PLCG2) and more calcium release. Tissue factor also binds to factor VII in the blood, which initiates the extrinsic coagulation cascade to increase thrombin production. Thrombin is a potent platelet activator, acting through Gq and G12. These are G protein-coupled receptors and they turn on calcium-mediated signaling pathways within the platelet, overcoming the baseline calcium efflux. Families of three G proteins (Gq, Gi, G12) operate together for full activation. Thrombin also promotes secondary fibrin-reinforcement of the platelet plug. Platelet activation in turn degranulates and releases factor V and fibrinogen, potentiating the coagulation cascade. Platelet plugging and coagulation occur simultaneously, with each inducing the other to form the final fibrin-crosslinked thrombus.
The growing number of smart ports around the world are increasing capacity and efficiency for shippers, ports, and freight forwarding partners, such as trucking carriers. Reductions in labour and machinery costs can be seen at ports thanks to improvements in automated and semi-automated cranes, which reduce the need for yard transfer vehicles. In 2018, shipping conglomerate Maersk partnered with IBM to create TradeLens, a platform for sharing and streamlining shipping information across shipping partners, businesses, and different authorities. By 2019, the platform covered nearly half of the world’s shipments of cargo containers.
As of 2008, no açaí products have been evaluated by the FDA, and their efficacy is doubtful. As of 2009, there is no scientific evidence that açaí consumption affects body weight, promotes weight loss or has any positive health effect.
Sources: en.wikipedia.org
He beat Andrey Rublev for the 17th title of his career and the fourth of the season, in 59 minutes, the shortest match in the tournament history. At the US Open, Zverev sought to claim his first major title following his run to the final the previous year. He reached the semifinals following wins over Jack Sock and Lloyd Harris. There, he lost to Novak Djokovic in five sets despite taking the first set, ending his career-high 16-match win streak stretching back to the Olympics. Zverev was seeded 3rd at the 2021 BNP Paribas Open, where he reached the quarterfinals. On the way, he defeated Jenson Brooksby, Andy Murray and Gaël Monfils. He lost to Taylor Fritz, despite having two match points. At the Erste Bank Open in Vienna, seeded second, he defeated Filip Krajinović and Alex de Minaur to reach the quarterfinals. The victory over De Minaur gave Zverev his 300th ATP tour match win. He then beat Félix Auger-Aliassime and Carlos Alcaraz to reach the final where he won his fifth title of the year and 18th overall, defeating Frances Tiafoe in straight sets. Zverev was the fourth seed at the 2021 Rolex Paris Masters. He received a bye into the second round, where he defeated Dušan Lajović. He defeated next sixteenth seed Grigor Dimitrov in the third round and sixth seed Casper Ruud in the quarterfinals. He lost in the semifinals to second seed Daniil Medvedev in straight sets. As a result of this run he equaled his singles career-high ranking of World No. 3 on 8 November 2021. For a fifth successive season, Zverev qualified for the 2021 ATP Finals in Turin, as the third seed.
Cossack relations with the Tsardom of Russia were varied from the outset. At times they supported Russian military operations, at other times they rebelled against the central power. After one such uprising at the end of the 18th century, Russian forces destroyed the Zaporozhian Host. Many of the Cossacks who had remained loyal to the Russian Monarch and continued their service later moved to the Kuban. Others, choosing to continue a mercenary role, escaped control in the large Danube Delta. The service of the Cossacks in the Napoleonic wars led them to be celebrated as Russian folk heroes, and throughout the 19th century a "powerful myth" was promoted by the government that portrayed the Cossacks as having a special and unique bond to the Emperor. This image of the Cossacks as ultra-patriotic defenders of not only Russia, but also of the House of Romanov was embraced by many ordinary Cossacks, making them into a force for conservatism. By the 19th century, the Russian Empire had annexed the territory of the Cossack Hosts, and controlled them by providing privileges for their service such as exemption from taxation and allowing them to own the land they farmed. At this time, the Cossacks served as military forces in many wars conducted by the Russian Empire. Cossacks were considered excellent for scouting and reconnaissance duties, and for ambushes. Their tactics in open battle were generally inferior to those of regular soldiers, such as the Dragoons.
==== Adaptive value ==== Cephalopods utilize chromatophores' color changing ability in order to camouflage themselves. Chromatophores allow coleoids to blend into many different environments, from coral reefs to the sandy sea floor. The color change of chromatophores works in concert with papillae, epithelial tissue which grows and deforms through hydrostatic motion to change skin texture. Chromatophores are able to perform two types of camouflage, mimicry and color matching. Mimicry is when an organism changes its appearance to appear like a different organism. The squid Sepioteuthis sepioidea has been documented changing its appearance to appear as the non threatening herbivorous parrotfish to approach unaware prey. The octopus Thaumoctopus mimicus is known to mimic a number of different venomous organisms it cohabitates with to deter predators. While background matching, a cephalopod changes its appearance to resemble its surroundings, hiding from its predators or concealing itself from prey. The ability to both mimic other organisms and match the appearance of their surroundings is notable given that cephalopods' vision is monochromatic. Cephalopods also use their fine control of body coloration and patterning to perform complex signaling displays for both conspecific and intraspecific communication. Coloration is used in concert with locomotion and texture to send signals to other organisms. Intraspecifically this can serve as a warning display to potential predators.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.